Actively Recruiting
Evaluating the Safety and Effectiveness of Intrathecal Onasemnogene Abeparvovec-brve in People with Spinal Muscular Atrophy A U.S. Multicenter Pragmatic Study
Led by Novartis Pharmaceuticals · Updated on 2026-10-29
36
Participants Needed
6
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of intrathecal onasemnogene abeparvovec-brve ITVISMA4 in people with genetically confirmed Spinal Muscular Atrophy SMA. This phase 4, pragmatic multicenter study in the U.S. follows participants who receive a single dose of this treatment. The study aims to fill important gaps in understanding SMA treatment outcomes by comparing each participants progress to their own baseline, using an external comparison group from medical records to provide context. Participants receive a one-time dose of onasemnogene abeparvovec-brve administered via lumbar puncture, along with systemic corticosteroid prophylaxis as per label instructions. The study includes independently ambulatory children and adolescents aged 2 to under 18 years, independently ambulatory adults aged 18 years and older, and non-ambulatory adults aged 18 years and older with specific motor function at baseline. No placebo or randomization is used, and participants act as their own comparators. During the study, participants are assessed at baseline and at 6, 12, 18, and 24 months for motor function changes using scales like HFMSE and RULM. Additional evaluations include caregiver experience, hospital visits, respiratory and nutritional support, joint range, and walking tests. Safety is monitored for up to 5 years. The study will last until June 2032, with ongoing follow-up to understand long-term effects and treatment impact.
CONDITIONS
Brief Title
ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here